Sensorion provides update on SENS-401 SSNHL Phase 2 AUDIBLE-S trial enrollment
(WorldNews France)

Sensorion provides update on SENS-401 SSNHL Phase 2 AUDIBLE-S trial enrollment 13 Mar 2020 07:30 CET Company Name SENSORION ISN FR0012596468 Market Euronext Growth Symbol ALSEN Regulatory News: Sensorion (FR0012596468 - ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announced today an update on timelines for the ongoing Phase 2 study of SENS-401 to treat Sudden Sensorineural Hearing Loss (SSNHL). Patient recruitment rates from this trial now indicate the data will be available by mid-year 2021, which is later than previously announced. `The AUDIBLE-S trial is...